BioNTech SE (BNTX) Income from Continuing Operations (2018 - 2025)
BioNTech SE (BNTX) posted Income from Continuing Operations of 174373718.5 for Q4 2025, down 419.71% on a QoQ basis from 33551881.12 in Q3 2025, and down 147.59% year-over-year from 366421362.72 in Q4 2024.
BioNTech SE (BNTX) has 8 years of Income from Continuing Operations data on file, last reported at 174373718.5 in Q4 2025.
- In Q4 2025, Income from Continuing Operations fell 147.59% year-over-year to 174373718.5; the TTM figure through Dec 2025 stood at 1082914764.96 (down 52.42% YoY), while the FY2025 annual figure was 1283578492.83, down 80.55% from the prior year.
- Income from Continuing Operations slipped to 174373718.5 in Q4 2025, from 33551881.12 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 7221719704.56 in Q3 2021 and bottomed at 865602233.83 in Q2 2024.
- A 5-year average of 1478353739.44 and a median of 452726812.25 in 2024 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2021 — Income from Continuing Operations soared 1637460123.4% — and 2024, when it tumbled 163.51%.
- Year by year, Income from Continuing Operations stood at 7163088507.63 in 2021, then slumped by 67.54% to 2324837671.3 in 2022, then sank by 59.81% to 934453810.95 in 2023, then tumbled by 60.79% to 366421362.72 in 2024, then slumped by 147.59% to 174373718.5 in 2025.
- The last three Income from Continuing Operations figures came in at 174373718.5 (Q4 2025), 33551881.12 (Q3 2025), and 437615615.38 (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -8.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.40 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 205.99 Mn |
| 10 | BioNTech SE | 27.66 Bn | 7.53 Bn | 668.28 Mn | -174.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -355.03 Mn |
| Sep 30, 2025 | 91.30 Mn |
| Jun 30, 2025 | -437.62 Mn |
| Mar 31, 2025 | -499.65 Mn |
| Dec 31, 2024 | 277.30 Mn |
| Sep 30, 2024 | 217.56 Mn |
| Jun 30, 2024 | -869.91 Mn |
| Mar 31, 2024 | -378.60 Mn |
| Dec 31, 2023 | 934.45 Mn |
| Sep 30, 2023 | 320.26 Mn |
| Jun 30, 2023 | -207.33 Mn |
| Mar 31, 2023 | 980.18 Mn |
| Dec 31, 2022 | 2.32 Bn |
| Sep 30, 2022 | 1.80 Bn |
| Jun 30, 2022 | 3.17 Bn |
| Mar 31, 2022 | 7.11 Bn |
| Dec 31, 2021 | 3.62 Bn |
| Sep 30, 2021 | 1.72 Bn |
| Jun 30, 2021 | 6.33 Bn |
| Mar 31, 2021 | 1.98 Bn |
| Dec 31, 2020 | 52.82 |
| Sep 30, 2020 | 242.38 Mn |
| Jun 30, 2020 | 97.26 Mn |
| Mar 31, 2020 | 58.95 Mn |
| Dec 31, 2019 | 16,603.32 |
| Sep 30, 2019 | 33.50 Mn |
| Jun 30, 2019 | 56.26 Mn |
| Mar 31, 2019 | 46.32 Mn |
| Dec 31, 2018 | -52.02 Mn |
| Sep 30, 2018 | 27.31 Mn |